Find out more

JUST A LITTLE BIT ABOUT US

ECBio’s main goal is to become a leading company in the development of innovative therapies involving the use of human stem cells.

Presently, ECBio´s main activity is organized in two business areas:

about02

1. Development of technologies for isolation and cryopreservation of foetal and adult stem cells.

2. Translation of stem cell technologies into cell-based therapies.

2. Translation of stem cell technologies into cell-based therapies.

At ECBio, a new method has been developed for isolation of a homogenous population of mesenchymal stem/stromal cells from the umbilical cord tissue. The method is the basis for the production of ECBio’s main stem cell product – UCX®. Currently, UCX® cells are being used as active substance for the production of several off-the-shelf biopharmaceutical medicines at the point of initiating clinical trials. ECBio focus on unmet medical needs in the of areas of cardiovascular disorders, such as peripheral artery disease and myocardial infarction; and immune-related disorders, such as rheumatoid arthritis.

Find out more

Latest From Our News

Events

Untitled-1

Stem cell events, meetings and conferences from the reliable EuroStemCell.

Independent and road-tested educational information and resources on stem cells and their impact on society. Funded by the European Commission.

Events

Some useful links